AXSM - דינמיקת הכנסות משנה לשנה ב-12 החודשים האחרונים Axsome Corp

Axsome Therapeutics (AXSM) profit dynamics depend on the commercialization of Auvelity and the success of new molecules. Year-over-year sales volatility over a rolling 12-month period visualizes this process, where 54.00 serves as the current parameter value. Growth is based on the creation of new treatment protocols for mental disorders, while inventory management flexibility is ensured by engaging external contract manufacturers.

Comparing assets requires an objective assessment of business expansion rates. The year-over-year (TTM) sales growth calculation is based on a rolling annual window, which neutralizes quarterly volatility and demonstrates the actual speed of revenue scaling. For Axsome Therapeutics (AXSM), this trend reflects the commercialization of neurobiological developments following rigorous clinical trials. Analyzing year-over-year (TTM) sales growth helps align the cost of the scientific mission with actual market success.